HYRIMOZ (adalimumab-adaz) · Novartis
Hyrimoz is a tumor necrosis factor (TNF) blocker indicated for the treatment of various chronic inflammatory and autoimmune conditions in both adult and pediatric patients. It is used to manage several arthritic conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. The medication is also approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. In many of these conditions, the drug's therapeutic role is to reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function.
How HYRIMOZ Works
Hyrimoz functions by specifically binding to TNF-alpha, a cytokine that plays a central role in normal and pathologic inflammatory and immune responses. By binding to TNF-alpha, the drug prevents it from interacting with the p55 and p75 cell surface TNF receptors, effectively blocking its biological activity. Additionally, the drug can cause the lysis of cells expressing surface TNF in the presence of complement. This mechanism helps modulate biological responses and reduce the elevated TNF concentrations found in the synovial fluid and skin plaques of patients with these inflammatory diseases.
Details
- Status
- Prescription
- First Approved
- 2018-10-30
- Patent Cliff
- 2025
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
HYRIMOZ Approval History
What HYRIMOZ Treats
9 indicationsHYRIMOZ is approved for 9 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Chronic Plaque Psoriasis
- Hidradenitis Suppurativa
- Uveitis
HYRIMOZ Boxed Warning
SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including HYRIMOZ, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HYRIMOZ if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberc...
WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including HYRIMOZ, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HYRIMOZ if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HYRIMOZ use and during therapy. Initiate treatment for latent TB prior to HYRIMOZ use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HYRIMOZ prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HYRIMOZ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products
HYRIMOZ Target & Pathway
ProTarget
A pro-inflammatory cytokine that plays a central role in immune responses and inflammation. Excess TNF contributes to autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Blocking TNF reduces inflammation and prevents tissue damage.
Pharmacists can substitute HYRIMOZ for Humira without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
HYRIMOZ Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in HYRIMOZ's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications HYRIMOZ treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to HYRIMOZ
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Novartis's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
HYRIMOZ FDA Label Details
Indications & Usage
FDA Label (PDF)HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . • Redu...
WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including HYRIMOZ, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these inf...
Explore on TheraRadar
Crohn's Disease Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.